Dyne Therapeutics, Inc. DYN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s cash & equivalents?
- Dyne Therapeutics, Inc. (DYN) reported cash & equivalents of $753.1M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Dyne Therapeutics, Inc.'s cash & equivalents increased by 59.5% year-over-year, from $472.26M to $753.1M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s cash & equivalents has grown at a 24.3% compound annual growth rate (CAGR), from $300.85M to $893.37M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.